234 related articles for article (PubMed ID: 27772740)
21. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
Savin Z; Lejbkowicz I; Glass-Marmor L; Lavi I; Rosenblum S; Miller A
J Neurol Sci; 2016 Jan; 360():102-9. PubMed ID: 26723984
[TBL] [Abstract][Full Text] [Related]
22. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
23. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
Fernandez O; Berger T; Hartung HP; Putzki N
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
[TBL] [Abstract][Full Text] [Related]
24. Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
Valet M; El Sankari S; Van Pesch V; Detrembleur C; Lejeune T; Stoquart G
Clin Biomech (Bristol, Avon); 2021 Jun; 86():105382. PubMed ID: 34000628
[TBL] [Abstract][Full Text] [Related]
25. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.
Weller D; Lörincz L; Sutter T; Reuter K; Linnebank M; Weller M; Zörner B; Filli L
J Neurol Sci; 2020 Sep; 416():116978. PubMed ID: 32559515
[TBL] [Abstract][Full Text] [Related]
26. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
Cardenas DD; Ditunno JF; Graziani V; McLain AB; Lammertse DP; Potter PJ; Alexander MS; Cohen R; Blight AR
Spinal Cord; 2014 Jan; 52(1):70-6. PubMed ID: 24216616
[TBL] [Abstract][Full Text] [Related]
27. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
[TBL] [Abstract][Full Text] [Related]
28. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
29. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study.
Jensen HB; Nielsen JL; Ravnborg M; Dalgas U; Aagaard P; Stenager E
Mult Scler Relat Disord; 2016 Nov; 10():137-144. PubMed ID: 27919481
[TBL] [Abstract][Full Text] [Related]
30. Effect of fampridine on axonal excitability in multiple sclerosis.
Huynh W; Pickering H; Howells J; Murray J; Cormack C; Lin CS; Vucic S; Kiernan MC; Krishnan AV
Clin Neurophysiol; 2016 Jul; 127(7):2636-42. PubMed ID: 27291883
[TBL] [Abstract][Full Text] [Related]
31. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T
Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976
[TBL] [Abstract][Full Text] [Related]
32. Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.
Prugger M; Berger T
Patient Relat Outcome Meas; 2013; 4():75-85. PubMed ID: 24187513
[TBL] [Abstract][Full Text] [Related]
33. Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study.
Bakirtzis C; Konstantinopoulou E; Langdon DW; Grigoriadou E; Minti F; Nikolaidis I; Boziki MK; Tatsi T; Ioannidis P; Karapanayiotides T; Afrantou T; Hadjigeorgiou G; Grigoriadis N
J Neurol Sci; 2018 Dec; 395():106-112. PubMed ID: 30308444
[TBL] [Abstract][Full Text] [Related]
34. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
Preiningerova JL; Baumhackl U; Csepany T; Czaplinski A; Deisenhammer F; Derfuss T; Fabjan TH; Fazekas F; Fuchs S; Havrdova E; Ledinek AH; Illes Z; Jazbec SS; Klimova E; Komoly S; Kurca E; Linnebank M; Lisy L; Mares J; Prochazkova L; Csilla R; Szilasiova J; Stourac P; Talab R; Turcani P; Vachova M; Vecsei L; Vodusek D; Zapletalova O; Berger T
CNS Neurosci Ther; 2013 May; 19(5):302-6. PubMed ID: 23607697
[TBL] [Abstract][Full Text] [Related]
35. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Korenke AR; Rivey MP; Allington DR
Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
[TBL] [Abstract][Full Text] [Related]
36. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study.
Mitsikostas DD; Doskas T; Gkatzonis S; Fakas N; Maltezou M; Papadopoulos D; Gourgioti R; Mitsias P
Adv Ther; 2021 Mar; 38(3):1536-1551. PubMed ID: 33528792
[TBL] [Abstract][Full Text] [Related]
37. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
[TBL] [Abstract][Full Text] [Related]
38. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
[TBL] [Abstract][Full Text] [Related]
39. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.
Kanhai KMS; Nij Bijvank JA; Wagenaar YL; Klaassen ES; Lim K; Bergheanu SC; Petzold A; Verma A; Hesterman J; Wattjes MP; Uitdehaag BMJ; van Rijn LJ; Groeneveld GJ
CNS Neurosci Ther; 2019 Jun; 25(6):697-703. PubMed ID: 30756475
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
